chimerix jazz - Search News

Jazz, Chimerix

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

Jazz Pharmaceuticals JAZZ announced that it has entered into a definitive agreement to acquire all the outstanding shares of clinical-stage biotech Chimerix CMRX for $8.55 per share in cash, aggregating to nearly $935 million.

Fierce Biotech · 4d

Jazz hands over $935M to buy Chimerix for near-approval cancer drug

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO

GlobalData on MSN · 3d

Jazz Pharmaceuticals bids for Chimerix in $935m deal

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal, disclosed on Wednesday 5 March, will see Jazz pay $8.

Jazz Buys Chimerix - A Good Deal To Make With Major Approval Catalyst In Play

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

MedCity News3d

First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal

Jazz Pharmaceuticals is now committing $935 million to add this prospect to its pipeline. The drug, dordaviprone, was developed by Durham, North Carolina-based Chimerix. The cancer is H3 K27M ...

Here are highlights from Friday’s Analyst Blog:

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an ...

Chimerix downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results